Compare RA & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RA | VALN |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 705.0M | 536.9M |
| IPO Year | 2016 | 2021 |
| Metric | RA | VALN |
|---|---|---|
| Price | $13.12 | $6.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 139.9K | 137.7K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $93.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.46 | $5.43 |
| 52 Week High | $13.59 | $12.25 |
| Indicator | RA | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 56.30 | 28.82 |
| Support Level | $12.87 | $5.88 |
| Resistance Level | $13.30 | $6.73 |
| Average True Range (ATR) | 0.15 | 0.28 |
| MACD | 0.05 | 0.04 |
| Stochastic Oscillator | 86.57 | 29.42 |
Brookfield Real Assets Income Fund Inc. is a diversified, closed-end management investment company. The investment objective of the Fund is to seek high total return, through high current income and secondarily, through growth of capital. The Fund seeks to achieve its investment objective by investing in the real asset class, which includes the following: Real Estate Securities, Infrastructure Securities, and Natural Resources Securities. The Fund operates in a single operating segment.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.